Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biontech Se ADR
(NQ:
BNTX
)
85.19
-2.06 (-2.36%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biontech Se ADR
< Previous
1
2
3
4
5
6
7
8
9
...
54
55
Next >
Cracking The Code: Understanding Analyst Reviews For BioNTech
March 21, 2024
Via
Benzinga
BioNTech Se (BNTX) Q4 2023 Earnings Call Transcript
March 20, 2024
BNTX earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 20, 2024
Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and...
Via
Benzinga
BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials
March 20, 2024
BioNTech SE (NASDAQ: BNTX) is way past its glorious Covid-19 days, when it thrived with Pfizer Inc (NYSE: PFE) for saving the world from the pandemic with their jointly developed vaccine.
Via
Benzinga
Exposures
COVID-19
Earnings Outlook For BioNTech
March 19, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For BioNTech
February 20, 2024
Via
Benzinga
Key Takeaways From BioNTech Analyst Ratings
January 23, 2024
Via
Benzinga
Stocks Quietly Higher As Central Bank Wraps Up Meeting
March 20, 2024
Stocks are cautiously higher ahead of the conclusion of the central bank's policy meeting.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q4 2023
March 20, 2024
BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
BioNTech Tumbles As Fourth-Quarter Sales Dive 65% And Miss Forecasts
March 20, 2024
BioNTech also reported plummeting earnings that missed forecasts and issued light 2024 guidance.
Via
Investor's Business Daily
Why Is BioNTech Stock Trading Lower On Wednesday?
March 20, 2024
BioNTech reported Q4 2023 earnings below expectations, with EPS at €1.90 vs. €9.26 last year. Sales were €1.479 billion, missing consensus. Guidance for 2024 anticipates revenues of €2.5-€3.1 billion,...
Via
Benzinga
US Stock Futures Stall As Traders Await Fed Chair Powell's Decision; Analyst Sees S&P 500 Showing 'Signs Of Near-Term Top'
March 20, 2024
Investors remain cautious ahead of the Federal Reserve‘s interest rate decision, with stock futures on Wednesday hinting at a lower opening.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Earnings Scheduled For March 20, 2024
March 20, 2024
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ:TIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million.
Via
Benzinga
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
March 13, 2024
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.
Via
InvestorPlace
The Short List: 3 Meme Stock Battlegrounds to Keep on Your Radar
March 06, 2024
Explore the ups and downs of 3 meme stocks: Imperial Petroleum, Novavax and MicroCloud, as they navigate market challenges and speculation.
Via
InvestorPlace
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
March 06, 2024
With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector.
Via
InvestorPlace
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
March 04, 2024
While red ink signals danger, for these oversold stocks ready for rebound, they could imply upside opportunities.
Via
InvestorPlace
It’s Time! 3 Dodgy Pharma Stocks to Sell in February
March 04, 2024
Explore pharma stocks to sell in February: Eli Lilly, Amgen, BioNTech face overvaluation, volatility, urging investor action.
Via
InvestorPlace
5 Value Stocks In The Healthcare Sector
March 04, 2024
Via
Benzinga
Overview Of Value Stocks In The Healthcare Sector
February 12, 2024
Via
Benzinga
3 Blue-Chip Stocks to Buy at a 52-Week Low in February
February 07, 2024
Higher-for-longer interest rates and undervalued metrics make it a good time to look for blue-chip stocks at a low price.
Via
InvestorPlace
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
February 03, 2024
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.
Via
Talk Markets
3 Pharma Stocks to Sell in February Before They Crash and Burn
February 02, 2024
The good times are coming to an end for these overpriced pharma stocks to sell this month before they crash and burn.
Via
InvestorPlace
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
January 30, 2024
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions.
Via
Benzinga
Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From China
January 27, 2024
ArriVent BioPharma priced its upsized Nasdaq IPO at $18 dollars per share, raising $175 million. The company’s stated goal is to find promising novel assets from China and other countries, which it...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
January 25, 2024
These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions.
Via
InvestorPlace
Enphase Energy To Rally Over 35%? Here Are 10 Top Analyst Forecasts For Tuesday
January 23, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive'
January 17, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here.
Via
Benzinga
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
January 13, 2024
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
54
55
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.